GSK vs SNY: stock comparison and AI forecast
Gsk Plc (GSK) and Sanofi (SNY) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
GSK Gsk Plc
- Price
- $50.41 -0.2% · 6M
- Market Cap
- $101.70B
- P/E Ratio
- 5.6x
- Size
- large-cap
- AI Forecast
SNY Sanofi
- Price
- $46.91 +8.6% · 6M
- Market Cap
- $115.65B
- P/E Ratio
- –
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- SNY is 1.1 times larger than GSK by market capitalization ($115.65B against $101.70B).
- Over the last six months SNY returned +8.6% and GSK -0.2%.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | GSK | SNY |
|---|---|---|
| Market Cap | $101.70B | $115.65B |
| P/E Ratio | 5.55x | – |
| EPS | $9.08 | – |
| Revenue/Share | $81.00 | – |
| FCF/Share | $15.23 | – |
Profitability & Margins
| Metric | GSK | SNY |
|---|---|---|
| ROE | – | 30.0% |
| ROA | – | 16.9% |
| ROIC | – | 20.7% |
| Gross Margin | 70.8% | – |
| Operating Margin | 20.3% | – |
| EBT Margin | 18.2% | – |
| Tax Rate | 13.7% | – |
Financial Health
| Metric | GSK | SNY |
|---|---|---|
| Current Ratio | 0.82x | 1.09x |
| Quick Ratio | 0.54x | 0.73x |
| D/E Ratio | 2.76x | – |
| Financial Leverage | – | 1.78x |
| Working Capital | -$5.23B | $3.06B |
Cash Flow
| Metric | GSK | SNY |
|---|---|---|
| Operating Cash Flow | $37.61B | $28.11B |
| Free Cash Flow | $30.73B | – |
| Capital Spending | -$6.88B | – |
| OCF Growth YoY | -13.3% | -11.9% |
| FCF Growth YoY | 0.0% | – |
| FCF/Sales | 18.8% | – |
| CapEx/Sales | 4.2% | – |
Operational Efficiency
| Metric | GSK | SNY |
|---|---|---|
| Receivables Turnover | 16.6x | – |
| Inventory Turnover | 6.1x | 3.8x |
| Fixed Assets Turnover | 13.3x | – |
| Days Sales Outstanding | 22 days | – |
| Days Inventory | 60 days | 96 days |
| Payables Period | 155 days | – |
| Cash Conversion Cycle | -73 days | – |
Income Statement
| Metric | GSK | SNY |
|---|---|---|
| Total Revenue | $163.43B | – |
| Operating Income | $33.20B | $23.11B |
| Net Income | – | $24.28B |
| R&D Expense | $33.87B | $25.35B |
| SG&A Expense | $50.02B | $32.28B |
| Cost of Goods Sold | $47.81B | $44.17B |
Dividend & Shareholder Information
| Metric | GSK | SNY |
|---|---|---|
| Shares Outstanding | 2017M | 2465M |
| Net Income Growth | – | 5.1% |
| EPS Growth | 87.6% | – |
GSK vs SNY: stock comparison and AI forecast
Which is bigger, GSK or SNY?
SNY is 1.1 times larger than GSK by market capitalization ($115.65B against $101.70B).
Which stock performed better over the last six months, GSK or SNY?
Over the last six months SNY returned +8.6% and GSK -0.2%.
Which one does Intratio's AI model rank higher, GSK or SNY?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.